Report Categories
View AllRecent Articles
View All
TNDM Tandem posts far narrower than expected Q4 2025 loss yet shares slip 115 percent today
AbbVie Inc ABBV Submits SKYRIZI Subcutaneous Crohns Regimen to FDA But NearTerm Upside Remains Capped By Competitive Risks
BSBK Bogota FinCo posts Q1 2025 EPS of 006 slips 053 as investors digest lack of performance forecasts